Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) CEO Craig A. Wheeler Sells 4,581 Shares

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) CEO Craig A. Wheeler sold 4,581 shares of the company’s stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $32.01, for a total transaction of $146,637.81. Following the completion of the transaction, the chief executive officer now owns 18,665 shares of the company’s stock, valued at $597,466.65. The sale was disclosed in a filing with the SEC, which is available at this link.

Shares of MNTA stock opened at $31.88 on Friday. The company’s 50-day moving average is $26.17 and its 200 day moving average is $17.38. The company has a market capitalization of $3.16 billion, a price-to-earnings ratio of -14.69 and a beta of 2.01. Momenta Pharmaceuticals, Inc. has a one year low of $9.51 and a one year high of $32.37.

Several research analysts have commented on the stock. Piper Sandler upped their price objective on shares of Momenta Pharmaceuticals from to in a report on Wednesday, February 5th. SunTrust Banks upped their price objective on shares of Momenta Pharmaceuticals to and gave the stock a “buy” rating in a report on Wednesday, January 15th. JPMorgan Chase & Co. upgraded shares of Momenta Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $14.00 to $30.00 in a report on Tuesday, January 14th. ValuEngine lowered shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, December 24th. Finally, HC Wainwright upped their price objective on shares of Momenta Pharmaceuticals from to and gave the stock a “buy” rating in a report on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $31.79.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Meeder Asset Management Inc. boosted its holdings in shares of Momenta Pharmaceuticals by 362.0% during the 4th quarter. Meeder Asset Management Inc. now owns 2,421 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 1,897 shares during the last quarter. Smith Asset Management Group LP purchased a new stake in shares of Momenta Pharmaceuticals during the 4th quarter valued at about $62,000. Nisa Investment Advisors LLC boosted its holdings in shares of Momenta Pharmaceuticals by 611.9% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,770 shares of the biotechnology company’s stock valued at $94,000 after acquiring an additional 4,100 shares during the last quarter. Teza Capital Management LLC purchased a new stake in shares of Momenta Pharmaceuticals during the 4th quarter valued at about $228,000. Finally, Victory Capital Management Inc. boosted its holdings in shares of Momenta Pharmaceuticals by 22.0% during the 4th quarter. Victory Capital Management Inc. now owns 14,083 shares of the biotechnology company’s stock valued at $409,000 after acquiring an additional 2,541 shares during the last quarter. 97.03% of the stock is currently owned by hedge funds and other institutional investors.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.

Further Reading: What is a Call Option?

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.